Pioglitazone improves skeletal muscle functions in reserpine-induced fibromyalgia rat model

Abstract

Abstract Background Fibromyalgia (FM) is characterized by musculoskeletal pain, fatigue, sleep and memory disturbance. There is no definitive cure yet for FM-related health problems. Peroxisome proliferator-activated receptor’s (PPAR’s) activation is associated with insulin sensitisation and improved glucose metabolism. PPAR-γ was reported to alleviate FM allodynia. Limited data are discussing its effect on motor disorders. Objective To investigate the potential effect of PPAR-γ agonists (pioglitazone, as one member of thiazolidinediones (TZD)) on motor dysfunction in reserpine-induced FM in a rat model. Materials and methods Thirty-six male Wistar rats were divided into negative control (n\u2009=\u20099) and reserpine-induced FM (n\u2009=\u200927) groups. The latter was subdivided into three equal subgroups (n\u2009=\u20099), positive control (untreated FM model), pioglitazone-treated and GW9662-treated. We evaluated muscle functions and activity of chloramphenicol acetyltransferase, superoxide dismutase, malondialdehyde, and serum levels of interleukin-8 and monocyte chemoattractant protein-1. Results Pioglitazone significantly relieved fatigue, improved muscle performance, reduced inflammatory cytokines and enhanced antioxidant’s activity, while GW9662, a known PPAR-γ antagonist, aggravated the FM manifestations in the rat model. Conclusion PPAR-γ agonists show a promising role against FM-associated motor dysfunctions.